Mycophenolate mofetil for lupus related myelopathy [5]

Annals of the Rheumatic Diseases

Volumn 65, Issue 7, 2006, Pages 971-973

  Mok, C C ^a   Mak, A ^a   To, C H ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LUPUS VULGARIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SPINAL CORD DISEASE;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MUSCULAR DISEASES; MYCOPHENOLIC ACID;

EID: 33745714277     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.046615     Document Type: Letter

References (10)

1. Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41.
2. Barile L, Lavalle C. Transverse myelitis in systemic lupus erythematosus-the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol 1992;19:370-2.
3. Mok CC, Lau CS, Chan YET, Wong RWS. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment and outcome. J Rheumatol 1998;25:467-73.
4. Mok CC, Lau CS, Wong RWS. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831-7.
5. Pisoni CN, Sanchez FJ, Karim Y, Cuadrado MJ, D'Cruz DP, Abbs IC, et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005;32:1047-52.
6. Chan TM, Tse KC, Tang CS, Mok MY, Li FK, Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84.
7. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
8. Ahrens N, Salama A, Haas J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001;248:713-14.
9. Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol 1989;42:703-9.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.